Temporal Associations of the SARS-CoV-2 NP Antigen and Anti-Spike Total Ig Levels with Laboratory Parameters in a Greek Cohort of Hospitalized COVID-19 Patients

Table 1

Baseline characteristics of the study population.

	All patients (N = 40)	Mild-moderate cases (N = 12)	Severe-critical cases (N = 28)	values
Age, years, median (range)	59.5 (30–90)	56.5 (30–87)	59.5 (34–90)	ns
Time from symptom onset to hospitalization, days, median (range)	8 (1–18)	6.5 (1–15)	8.5 (1–18)	ns
Male sex, n (%)	31 (77.5%)	8 (66.7%)	23 (82.1%)	ns
Positive smoking history, n (%)	16 (40%)	5 (41.7%)	11 (39.3%)	ns
Comorbidities
Hypertension, n (%)	24 (60%)	4 (33.3%)	20 (71.4%)	0.024
Dyslipidemia, n (%)	12 (30%)	2 (16.7%)	10 (35.7%)	ns
Diabetes, n (%)	11 (27.5%)	1 (8.3%)	10 (35.7%)	ns
Coronary disease, n (%)	9 (22.5%)	1 (8.3%)	8 (28.6%)	ns
Obesity, n (%)	8 (20%)	1 (8.3%)	7 (25%)	ns
Immunosuppression, n (%)	4 (10%)	1 (8.3%)	3 (10.7%)	ns
Chronic obstructive pulmonary disease, n (%)	3 (7.5%)	1 (8.3%)	2 (7.1%)	ns
Any malignancy, n (%)	2 (5%)	1 (8.3%)	1 (3.6%)	ns
Chronic renal disease, n (%)	1 (2.5%)	0 (0%)	1 (3.6%)	ns
Other comorbidities, n (%)	27 (67.5%)	8 (66.7%)	19 (67.9%)	ns
Symptoms at admission
Fever, n (%)	39 (97.5%)	12 (100%)	27 (96.4%)	ns
Shortness of breath, n (%)	22 (55%)	5 (41.7%)	17 (60.7%)	ns
Cough, n (%)	21 (52.5%)	6 (50%)	15 (53.6%)	ns
Weakness, n (%)	14 (35%)	5 (41.7%)	9 (32.1%)	ns
Arthralgia, n (%)	8 (20%)	4 (33.3%)	4 (14.3%)	ns
Headache, n (%)	5 (12.5%)	2 (16.7%)	3 (10.7%)	ns
Nausea, n (%)	4 (10%)	3 (25%)	1 (3.6%)	0.038
Chest pain, n (%)	3 (7.5%)	1 (8.3%)	2 (7.1%)	ns
Diarrhea, n (%)	3 (7.5%)	0 (0%)	3 (10.7%)	ns
Confusion, n (%)	1 (2.5%)	0 (0%)	1 (3.6%)	ns
Complications at admission
Pneumonia, n (%)	34 (85%)	9 (75%)	25 (89.3%)	ns
Acute kidney damage, n (%)	7 (17.5%)	1 (8.3%)	6 (21.4%)	ns
Acute respiratory distress syndrome, n (%)	3 (7.5%)	0 (0%)	3 (10.7%)	ns
Cardiovascular damage, n (%)	2 (5%)	0 (0%)	2 (7.1%)	ns
Multiple organ failure, n (%)	2 (5%)	0 (0%)	2 (7.1%)	ns